一种基于聚(I:C)/QS-21的原位疫苗与抗PD-1疗法协同作用,可有效克服肿瘤免疫耐药性。
A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance
Wenbo Zhang, Xinrui Ni, Luoyi Zhuo, Jiangrui Liu, Guang Yang, Jianming Li, Lingai Tang, Xiuli Du, Chun Shan, Guoqiang Feng, Wenguang Wang, Qi Gao, Qiang Sui, Min Xia, Chunwang Yuan, Dexiang Chen, Yon
Journal:Cell Reports Medicine
IF:14
DOI:10.1016/j.xcrm.2026.102932
PMID:42486097
Published:2026-07-22
research field:泌尿学药物递送系统生物材料纳米医学炎症性疾病活性氧生物学
Abstract
Despite remarkable advances in cancer immunotherapy, immunoresistance remains a critical barrier to its broader success. To address this challenge, we develop an adjuvant system that combines polyinosinic:polycytidylic acid (poly(I:C)) with QS-21 and functions as an in situ cancer vaccine, effectively boosting antitumor immunity across diverse tumor types. This synergistic formulation leverages QS-21-mediated cytosolic delivery of poly(I:C) to potentiate the TBK1-IRF3-type I interferon axis. This activation licenses robust IRF1 nuclear translocation as a downstream transcriptional integrator, thereby inducing immunogenic cell death in tumor cells. Intratumoral administration of this system enhances dendritic cell maturation and neoantigen presentation, which elicits a robust neoantigen-specific T cell response and generates protective immune memory that prevents tumor recurrence. Moreover, the adjuvant sensitizes tumors to anti-PD-1 therapy and, when combined with microwave ablation, significantly improves antitumor efficacy. Collectively, this approach offers a promising strategy to overcome immunoresistance and advance combination immunotherapies.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


